Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)
Scynexis' (SCYX) quarterly Cash from Financing Activities came in at $13.5 million in Q2 2026, down 44.01% quarter-over-quarter from $24.0 million in Q1 2026.
Analysis
Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Cash from Financing Activities for 14 consecutive years, with $13.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities changed N/A year-over-year to $13.5 million; the trailing twelve-month figure through Jun 2026 stood at $37.4 million (up 363.31% YoY), and the FY2025 full-year result was -$14.2 million, down 10094.24% from the prior year.
- Cash from Financing Activities fell to $13.5 million in Q2 2026 per SCYX's latest filing, from $24.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $42.1 million in Q2 2022 and bottomed at -$36.6 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $2.3 million across 5 years, with a median of $22000.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 9569.01% in 2022, then sank 93793.33% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$183000.0 in 2022, then rose by 26.23% to -$135000.0 in 2023, then fell by 14.81% to -$155000.0 in 2024, then gained by 25.81% to -$115000.0 in 2025, then jumped by 11803.48% to $13.5 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $13.5 million, $24.0 million, and -$115000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 14.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -181.51 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 13.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.46 Mn |
| Mar 31, 2026 | 24.04 Mn |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -155,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | -36.64 Mn |
| Mar 31, 2023 | 22,000.00 |
| Sep 30, 2022 | -183,000.00 |
| Jun 30, 2022 | 42.06 Mn |
| Mar 31, 2022 | 6.72 Mn |
| Dec 31, 2021 | 30.48 Mn |
| Sep 30, 2021 | 4.53 Mn |
| Jun 30, 2021 | 32.18 Mn |
| Mar 31, 2021 | -71,000.00 |
| Dec 31, 2020 | 80.12 Mn |